- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Science
- Onco-Metabolism Platform
- Therapeutic Areas
- Publications
- Programs
- Pipeline
- Glutaminase Inhibitor CB‑839
- Arginase Inhibitor INCB001158
- Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Media & Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
Science
Publications and Presentations
Check out our publications and poster presentations.
June 2018
Phase 1 clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumorsAmerican Society of Clinical Oncology
June 2018
April 2018
The Glutaminase Inhibitor CB-839 Synergizes with CDK4/6 and PARP Inhibitors in Pre-Clinical Tumor ModelsAmerican Association of Cancer Research – 2018
February 2018
Phase I study of glutaminase inhibitor CB-839, combined with everolimus or cabozantinib in patients with clear cell and papillary renal cell carcinomaAmerican Society of Clinical Oncology Genitourinary Cancer Symposium
January 2018
Anti-Tumor Activity of Glutaminase Inhibitor CB-839 in Solid Tumor MalignanciesKeystone Tumor Metabolism
Our Pipeline
We are focused on solid tumors for
which new treatments are urgently needed.